| FORM | 4 |
|------|---|
|------|---|

| Check this box if no |
|-----------------------|
| longer subject to |
| Section 16. Form 4 or |
| Form 5 obligations |
| may continue. See |
| Instruction 1(b). |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type Responses) | | | | | | | | | | |
|---|--|---|----------------------------------|------|------------------------------------|---------------|---|--|----------------------------------|-------------------------|
| 1. Name and Address of Reporti Brandt Peter C. | 2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN] | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | |
| (Last) (First) C/O REXAHN PHARMAC INC., 15245 SHADY GRO | 3. Date of Earliest Transaction (Month/Day/Year) 09/06/2011 | | | | | | Officer (give title below) | Other (specify be | ow) | |
| (Street) ROCKVILLE, MD 20850 | | | | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person | | | |
| (City) (State) | (Zip) | Τε | ble I - Nor | -Der | ivative S | ecuritie | es Acqui | ired, Disposed of, or Beneficially (| Owned | |
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transac Code (Instr. 8) | tion | 4. Secur (A) or D (Instr. 3, | isposed | of (D) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: | Beneficial Ownership |
| | | (Month/Day/Tear) | Code | v | Amount | (A) or (D) | Price | (liisu: 5 and 4) | or Indirect (I) (Instr. 4) | |
| Common Stock | 09/06/2011 | | Р | | 3,250 | А | \$ 0.948 | 3,250 | D | |
| Common Stock | 09/06/2011 | | Р | | 2,450 | | + | 5,700 | D | |
| Common Stock | 09/06/2011 | | Р | | 5,300 | ٨ | ¢ | 11,000 | D | |
| Common Stock | 09/06/2011 | | Р | | 3,900 | А | \$ 0.945 | 14,900 | D | |
| Common Stock | 09/06/2011 | | Р | | 300 | Δ | \$ 0.944 | 15,200 | D | |
| Common Stock | 09/06/2011 | | Р | | 4,500 | А | \$ 0.945 | 19,700 | D | |
| Common Stock | 09/06/2011 | | Р | | 300 | Δ | ¢ | 20,000 | D | |
| Common Stock | 09/07/2011 | | Р | | 5,000 | А | \$ 1.04 | 25,000 | D | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

| | (<i>e.g.</i> , puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
|--|---|--------------------------|---|------|----------------------------------|-----|--|--|--------------------|--|--|-------------------------|--------|---|--|--------------------------------------|--|--|------------|
| | Conversion | Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | Code | 5. Number of de Derivative | | vative rities nired or osed 0) r. 3, | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 6. Date Exercisable and Expiration Date | | 6. Date Exercisable and | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | | Derivative Security (Instr. 5) | Derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form of Derivative Security: Direct (D) or Indirect | Beneficial |
| | | | | Code | v | (A) | | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | | | | |
| Stock Options (right- to-buy) | \$ 1.25 | | | | | | | <u>(1)</u> | 06/06/2021 | Common Stock | 20,000 | | 20,000 | D | | | | | |
| Stock Options (right- to-buy) | \$ 1.19 | | | | | | | <u>(2)</u> | 09/17/2020 | Common Stock | 20,000 | | 20,000 | D | | | | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | |
|--------------------------------|---------------|-----------|---------|-------|--|
| | Director | 10% Owner | Officer | Other | |

| Brandt Peter C. C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 | Х | | |
|--|---|--|--|
| ROCKVILLE, MD 20850 | | | |

Signatures

| /s/ Tae Heum Jeong, as attorney-in-fact for Peter C. Brandt | 09/08/2011 |
|---|------------|
| Signature of Reporting Person | Date |
| | |

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These options vest and become exercisable in full on June 6, 2012.

(2) These options vest and become exercisable in full on September 17, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.